Medtronic (BASE:MDTD) - Aandelenkoers, Nieuws & Analyse

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

MDTD Overzicht aandelen

Develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide.

Over het bedrijf

MDTD fundamentele analyse
Sneeuwvlok Score
Waardering	1/6
Toekomstige groei	1/6
Prestaties in het verleden	2/6
Financiële gezondheid	5/6
Dividenden	4/6

Beloningen

De winst zal naar verwachting met 11.15% per jaar groeien

Risicoanalyse

Aandelen zijn zeer illiquide

Dividend van 3.13% wordt niet goed gedekt door de winst

Medtronic plc Concurrenten

Boston Scientific

NYSE:BSX

US$129.7b

Stryker

NYSE:SYK

US$140.8b

Becton Dickinson

NYSE:BDX

US$70.5b

Intuitive Surgical

NasdaqGS:ISRG

US$185.6b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Medtronic
Historische aandelenkoersen
Huidige aandelenkoers	US$31.00
52 Week Hoogtepunt	US$0
52 Week Laag	US$0
Bèta	0.72
11 maand verandering	0%
3 maanden verandering	n/a
1 Jaar Verandering	n/a
33 jaar verandering	n/a
5 jaar verandering	n/a
Verandering sinds IPO	0%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	MDTD	AR Medical Equipment	AR Markt
7D	0%	0%	0%
1Y	n/a	0%	0%

Rendement versus industrie: Er zijn onvoldoende gegevens om te bepalen hoe MDTD presteerde ten opzichte van de AR Medical Equipment.

Rendement versus markt: Er zijn onvoldoende gegevens om te bepalen hoe MDTD presteerde ten opzichte van de AR markt.

Prijsvolatiliteit

Is MDTD's price volatile compared to industry and market?
MDTD volatility
MDTD Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	0%
Market Average Movement	0%
10% most volatile stocks in AR Market	0%
10% least volatile stocks in AR Market	0%

Stabiele aandelenkoers: MDTD heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van MDTD in het afgelopen jaar te bepalen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1949	95,000	Geoff Martha	www.medtronic.com

Medtronic plc Samenvatting

Hoe verhouden de winst en inkomsten van Medtronic zich tot de beurswaarde?
MDTD fundamentele statistieken
Marktkapitalisatie	US$115.93b
Inkomsten(TTM)	US$3.76b
Inkomsten(TTM)	US$31.23b

31.2x

Koers/Winstverhouding

3.8x

P/S-verhouding

Is MDTD overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
MDTD resultatenrekening (TTM)
Inkomsten	US$31.23b
Kosten van inkomsten	US$10.62b
Brutowinst	US$20.61b
Overige uitgaven	US$16.85b
Inkomsten	US$3.76b

Laatst gerapporteerde inkomsten

Apr 28, 2023

Volgende inkomensdatum

Aug 22, 2023

Winst per aandeel (EPS)	2.82
Brutomarge	65.98%
Nettowinstmarge	12.03%
Schuld/Eigen Vermogen Verhouding	47.0%

Hoe presteerde MDTD op de lange termijn?

Bekijk historische prestaties en vergelijking

Dividenden

3.1%

Huidig dividendrendement

96%

Uitbetalingsratio

MDTD Overzicht aandelen

Beloningen

Risicoanalyse

Medtronic plc Concurrenten

NYSE:BSX

US$129.7b

NYSE:SYK

US$140.8b

NYSE:BDX

US$70.5b

NasdaqGS:ISRG

US$185.6b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Voluntary Recall Notifying Medtronic Insulin Pump Users of Potential Risks of Shortened Pump Battery Life

Medtronic plc Announces the Presentation of Clinical Study Results

Medtronic plc Revises Earnings Guidance for the Fiscal Year 2025

Medtronic plc Announces Cash Dividend for Second Quarter of Fiscal Year 2025, Payable on October 11, 2024

Medtronic plc, Annual General Meeting, Oct 17, 2024

Medtronic plc Announces Resignation of Karen Parkhill as CFO

Recent updates

Voluntary Recall Notifying Medtronic Insulin Pump Users of Potential Risks of Shortened Pump Battery Life

Medtronic plc Announces the Presentation of Clinical Study Results

Medtronic plc Revises Earnings Guidance for the Fiscal Year 2025

Medtronic plc Announces Cash Dividend for Second Quarter of Fiscal Year 2025, Payable on October 11, 2024

Medtronic plc, Annual General Meeting, Oct 17, 2024

Medtronic plc Announces Resignation of Karen Parkhill as CFO

Medtronic plc Announces Retirement of Rob Ten Hoedt as Executive Vice President and President, Global Regions, Effective as of June 28, 2024

Medtronic plc Increases Cash Dividend for the First Quarter of Fiscal Year 2025, Payable on July 12, 2024

Medtronic plc Announces its Investigational OmniaSecure Defibrillation Lead Met its Primary Safety and Effectiveness Endpoints, Existing Safety and Effectiveness Endpoints

Medtronic plc Receives FDA Approval for Inceptiv Closed-Loop Spinal Cord Stimulator

Medtronic plc Announces New Advancements in Artificial Intelligence for Endoscopic Care by Unveiling ColonPRO

Medtronic plc Announces SMART Trial One-Year Data Demonstrates Medtronic Evolut™ Tavr Platform as Optimal Treatment for Severe Aortic Stenosis in Patients with Small Annulus, Which Is Primarily Women

Medtronic plc Presents New Clinical and Real-World Data on the MiniMed™ 780G System from Around the World

Medtronic plc Approves Cash Dividend for the Fourth Quarter of Fiscal Year 2024, Payable on April 12, 2024

Medtronic plc to Report Q3, 2025 Results on Feb 18, 2025

Medtronic plc Announces FDA Approval of Its Percept™? RC Deep Brain Stimulation System

Medtronic Diabetes Announces World's First Approval for MiniMed™ 780G System with Simplera Sync™ Disposable, all-in-one sensor

Medtronic plc Announces FDA Approves the PulseSelect Pulsed Field Ablation System for the Treatment of Both Paroxysmal and Persistent Atrial Fibrillation

Medtronic Announces Cash Dividend for Third Quarter of Fiscal Year 2024, Payable on January 12, 2024

Medtronic plc Revises Earnings Guidance for the Fiscal Year 2024

Medtronic plc Announces Four-Year Results from the Evolut Low Risk Trial

Orchestra BioMed Holdings, Inc Grants FDA Approval of IDE to Initiate BACKBEAT Pivotal Study of BackBeat CNT™ for the Treatment of Hypertension in Pacemaker Patients

Medtronic Issues Statement on the FDA Circulatory Systems Devices Advisory Panel vote for the Symplicity Spyral Renal Denervation System

Medtronic plc Raises Earnings Guidance for 2024

Medtronic plc Approves Cash Dividend for the Second Quarter of Fiscal Year 2024, Payable on October 13, 2023

Medtronic plc Appoints Greg Lewis as New Director

Medtronic plc Presents New Data on MiniMed 780G System on Fixed Meal Dosing and Real-World Time in Range Across Wide Range of Users

Medtronic plc Appoints Ken Washington as Chief Technology and Innovation Officer

Medtronic plc Approves Cash Dividend for the First Quarter of Fiscal Year 2024, Payable on July 14, 2023

Medtronic plc Announces Medtronic Extravascular ICD Global Clinical Trial Results Reinforce Device Safety and Effectiveness

Medtronic Extravascular ICD Global Clinical Trial Results Reinforce Device Safety and Effectiveness

Shockwave Medical Reportedly Picks Up Takeover Interest from Two Additional Suitors

Shockwave Medical Reportedly Picks Up Takeover Interest from Two Additional Suitors

Rendement voor aandeelhouders

Prijsvolatiliteit

Over het bedrijf

Medtronic plc Samenvatting

31.2x

3.8x

Inkomsten en omzet

Dividenden

3.1%

96%